PTX
data caveat$74MCF+
Prescient Therapeutics
Oncology
OmniCAR platform for T-cell therapy; PTX-100 PI3K inhibitor in haematologic cancers
Data HealthTrials1 of 1 active · stale enrollment
Cash data from Mar 2026 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$11.9M
Mar 2026 4C
Runway
CF+Cash Flow Positive
Based on Mar 2026 4C
Market Cap
$74M
Burn Rate
—
Mar 2026 4C
Shares Outstanding
1.1B
Pipeline Assets
3
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveQuarterly 4C29 Apr 2026
March 2026 Quarterly Update and Appendix 4C
Cash$11.9M·Burn$2.2M/q·OCF$2.2M·RDTI$4.4M
3M Price
PTX.ASX$0.065+14.0% 3M
Low $0.050High $0.082
Pipeline Assets (3)
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
R&D Tax Incentive
$4.4M received43.5% ATO refund
FY2026received
Auto-extracted from 4C (2026-03-31)
$4.36M
How the R&D Tax Incentive works
Australian biotechs with < $20M aggregated turnover can claim a 43.5% refundable tax offseton eligible R&D expenditure each financial year (Jul–Jun). This is paid as a cash refund by the ATO — not a tax deduction — making it non-dilutive capital that directly extends cash runway.
Companies register eligible R&D activities with AusIndustry during the year, then lodge their tax return after 30 June. Refunds typically arrive October–Decemberof the same calendar year. For a company spending $5M/year on R&D, this is a ~$2.2M annual cash inflow.
Disclaimer: Amounts shown as or are forward-looking estimates based on disclosed R&D expenditure and the 43.5% offset rate. Actual refunds may differ due to ATO assessments, eligibility rulings, or changes in R&D spend. This is not financial advice. Manually curated from 4C filings and company disclosures — verify independently.
Catalysts (1)
SpeculativeremoveMed1 Jan 2028
| Event | Type | Confidence | Impact | Date | Status |
|---|---|---|---|---|---|
| PHASE2 data readout — A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCLopen_in_new Primary completion expected for NCT06854653. Indication: {CTCL} | data readout | Speculative | removeMed | 1 Jan 2028 |
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High93/100(limited data)
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Filed 2 of 2 4Cs on time· statutory deadline
What drove these scores · rolling 2yr
arrow_drop_up
Cash-flow positive — 1/2 quarters with positive operating cash flow
arrow_drop_up
Cash position improving — Cash balance growing
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(3)
1 activeClinicalTrials.gov ↗
Ph2RecruitingEnrollment stale · 439d
PTX-100
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
CTCL
RandomizedOpen Label18 Years+
Primary endpoint To determine the efficacy of PTX-100 as determined by ORR.
ENROL115
no manual snapshots — enter via record_enrollment.py
Announcements(8)
payments
Quarterly 4CPSauto_awesome
March 2026 Quarterly Update and Appendix 4C29 Apr 2026
expand_more642KB
description
Half YearPSauto_awesome
Appendix 4D and Half Year Financial Report24 Feb 2026
expand_more1021KB